NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.

Hundreds of people with cystic fibrosis are to be offered a once-a-day pill which has been hailed as “life changing” by health experts.

Vertex Pharmaceuticals VRTX announced that the European Commission has approved Alyftrek ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...